Skye Bioscience Inc
Change company Symbol lookup
Select an option...
SKYE Skye Bioscience Inc
FRME First Merchants Corp
SFDMY Shanghai Fudan Microelectronics Group Co Ltd
NWL Newell Brands Inc
MRK Merck & Co Inc
FWONA Liberty Media Corp
RSG Republic Services Inc
TENB Tenable Holdings Inc
NLSN Nielsen Holdings PLC
CLAR Clarus Corp
Go

Health Care : Biotechnology |
Company profile

Skye Bioscience, Inc., formerly Emerald Bioscience, Inc., is a biopharmaceutical company, which is engaged in engineering cannabinoid derivatives to treat glaucoma and other diseases. The Company is focused on discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. Its programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. CBDVHS is a prodrug of cannabidiol (CBD) that has demonstrated biological activity in prodrug form (CBDVHS) and as native (natural) CBD. The Company has chemically-modified the CBD molecule to improve on its known positive effects.

Closing Price
$0.0622
Day's Change
0.0027 (4.54%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0699
Day's Low
0.056
Volume
(Heavy Day)
Volume:
1,620,861

10-day average volume:
1,034,625
1,620,861

Display:

Providers:

UpdateCancel
6 providers
October 21, 2021
Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today researchers...(Globe Newswire)

October 12, 2021
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive...(Globe Newswire)

October 07, 2021
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea...(Globe Newswire)

Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea...(Globe Newswire)

October 05, 2021
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms...(Globe Newswire)

September 29, 2021
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing...(Globe Newswire)

September 27, 2021
Skye Bioscience Announces $7.0 Million Registered Direct Offering

Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced that it has...(Globe Newswire)

September 21, 2021
Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, announced today its research partner, the University of Mississippi will...(Globe Newswire)

September 14, 2021
Skye Bioscience Announces Special Virtual Investor Presentation

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will host a special virtual investor...(Globe Newswire)

September 07, 2021
Skye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

EQNX::TICKER_START (Other OTC:SKYE),(OTC US:SKYE), EQNX::TICKER_END Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.